Plain-English translation of NCT06410833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
Sjogren's syndrome is an autoimmune disease that damages the glands that make tears and saliva, causing dry eyes and mouth. Some children and teens don't get better with standard treatments. This trial is testing whether a combination approach using two medications—first , then —can better control the disease in patients whose symptoms have proven hard to treat.
Many young patients with Sjogren's syndrome continue to have active disease even after trying multiple standard medications. Researchers want to know if using this treatment in a specific sequence can reduce disease activity and help these patients feel better.
You likely qualify if…
You likely don't qualify if…
You would receive infusions weekly for 2 to 4 weeks until your B cells reach a very low level. Four weeks after your last dose, you would start infusions every 4 weeks for a total of 7 doses, continuing through week 28 of the study. Doctors will measure your disease activity before and after treatment to see if this medication combination reduces your symptoms and inflammation.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
China